The PH Professional Network (PHPN) Symposium, “Influencing the Practice: The Art and Science of Treating Pulmonary Hypertension,” being held from Sept. 5-7 in Washington, D.C., will offer attendees informative sessions on the latest breakthroughs in PH research and treatment. Two sessions of note include updates on implantable pumps and oxygen delivery devices.
Attendees to “Implantable System for Remodulin for PAH: Free At Last…Or Maybe Not!” will hear how recent FDA approval of an implanted pump system for treprostinil offers a new, potentially game-changing choice for parenteral prostacyclin therapy. Based on published data and clinical experience with the implanted pump system, Wendy M. Hill, M.S.N., NP-C, Shelley M. Shapiro, M.D., Ph.D., and Glenna Traiger, R.N., M.S.N., CNS-BC, will present approaches to patient selection, transition from external pumps to the implanted pump, the implant/re-implant, pump filling procedure and discontinuation/explant, and explore unanswered questions.
As experts know, oxygen is a vital part of the treatment for many patients living with pulmonary hypertension, as are the devices they count on to deliver the oxygen. Experts Mary E. Whittenhall, N.P., and Tonya Zeiger, R.R.T., CPFT, will lead a session titled “Updates on Oxygen Delivery Devices” that outlines the new and challenging additions to the oxygen delivery world.
These sessions are two of the dozens of presentations to be held at the 2019 Symposium. Participants can earn up to 12.5 hours of CME/CEU.
Health care professionals can register for the PHPN Symposium at PHAssociation.org/Symposium/Registration.
